

# CHOOSE **BREZTRI<sup>®</sup>** **AEROSPHERE<sup>®</sup>** FOR ITS POWER TO REDUCE EXACERBATIONS IN COPD<sup>†</sup>



## **BUDESONIDE (ICS), GLYCOPYRRONIUM (LAMA), AND FORMOTEROL (LABA) IN 1 pMDI DEVICE\***

BREZTRI AEROSPHERE is indicated for the long-term maintenance treatment to reduce exacerbations of COPD and treat airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, who are not adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA.<sup>†</sup>

**Covered in ALL 10 provinces with special authorization<sup>2-13†</sup>**

\* Clinical significance has not been established.

† BREZTRI AEROSPHERE is eligible for reimbursement with special authorization in Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Quebec, Prince Edward Island, Saskatchewan, and the Non-Insured Health Benefits and Veteran Affairs Canada. Please refer to the respective formularies for coverage information.

COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroid; LABA: long-acting beta<sub>2</sub>-adrenergic agonist; LAMA: long-acting muscarinic antagonist; pMDI: pressurized metered-dose inhaler.



**BREZTRI<sup>®</sup>**  
**AEROSPHERE<sup>®</sup>**

budesonide / glycopyrronium / formoterol  
fumurate dihydrate pressurized inhalation  
suspension

COPD maintenance with dosing both day and night

# BREZTRI AEROSPHERE: TWICE-DAILY ADMINISTRATION WITH A SINGLE pMDI DEVICE<sup>1</sup>



**2** inhalations  
in the  
morning

+



**2** inhalations  
in the  
evening

## PHARMACODYNAMICS: BREZTRI AEROSPHERE ACHIEVED RAPID ONSET OF ACTION<sup>1\*</sup>



Improvement in FEV<sub>1</sub> within 5 minutes of the first dose  
on Day 1 (median time to  $\geq 100$  mL)

Please see the Product Monograph for full dosing information.

\*Clinical significance has not been established.

Consult the BREZTRI AEROSPHERE Product Monograph at [breztri-en.azpm.ca](https://www.breztri-en.azpm.ca) for important information about:

- Relevant warnings and precautions regarding risk of serious asthma-related events, deterioration of disease, excessive use with other LAMA and LABA products, anticholinergic activity, cardiovascular effects, driving and operating machinery, candidiasis, risk of systemic effects, hypercorticism and adrenal suppression, adrenal insufficiency in patients transferred from systemic steroid, patients with symptomatic prostatic hyperplasia, glaucoma, convulsive disorders, thyrotoxicosis, sensitivity to sympathomimetic amines, severe hepatic impairment/hepatic disease, or urinary retention, systemic eosinophilic conditions (in rare cases), susceptibility or decreased resistance to infections, monitoring, paradoxical bronchospasm, increased risk of pneumonia, pregnant and nursing women, and geriatrics.
- Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available by calling AstraZeneca Canada at **1-800-668-6000**.

COPD: chronic obstructive pulmonary disease; FEV<sub>1</sub>: forced expiratory volume in 1 second; LABA: long-acting beta<sub>2</sub>-adrenergic agonist; LAMA: long-acting muscarinic antagonist; pMDI: pressurized metered-dose inhaler.

**References:** 1. BREZTRI AEROSPHERE Product Monograph. AstraZeneca Canada Inc. 2. Government of British Columbia. Special Authority Drug List. Retrieved December 5, 2023, from <https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/special-authority/sa-drug-list>. 3. Government of Manitoba. Exception Drug Status. Retrieved December 5, 2023, from <https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf>. 4. Government of New Brunswick. New Brunswick Drug Plans Formulary. Retrieved December 5, 2023, from <https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/NewBrunswickDrugPlansFormulary.pdf>. 5. Government of Canada. Non-Insured Health Benefits: Formulary Search Results. Retrieved December 5, 2023, from <https://nihb-ssna.express-scripts.ca/en/0205140506092019/16/160407>. 6. Government of Newfoundland & Labrador. Special Authorization Criteria. Retrieved December 5, 2023, from <https://www.gov.nl.ca/hcs/prescription/covered-specialauthdrugs>. 7. Government of Nova Scotia. Appendix III - Criteria for Coverage of Exception Status Drugs. Retrieved December 5, 2023, from <https://novascotia.ca/dhw/pharmacare/documents/Criteria-for-Exception-Status-Coverage.pdf>. 8. Government of Ontario. Formulary / Comparative Drug Index Edition 43 Summary of Changes October 2022. Retrieved December 5, 2023, from <https://www.ontario.ca/document/ontario-drug-benefit-odb-formulary-comparative-drug-index-cdi-and-monthly-formulary-0>. 9. Government of Saskatchewan. Formulary Search Results. Retrieved December 5, 2023, from <https://formulary.drugplan.healthsask.ca/SearchFormulary.10>. 10. Alberta Health Services. Alberta Health Drug Benefit List. Retrieved December 5, 2023, from <https://idbl.ab.bluecross.ca/idbl/load.do>. 11. Health PEI. Pharmacare Bulletins. Retrieved December 5, 2023, from <https://src.healthpei.ca/pharmacare-bulletins>. 12. Veterans Affairs Canada. Drug Formulary Search Results. Retrieved December 5, 2023, from <https://www.veterans.gc.ca/eng/financial-support/medical-costs/treatment-benefits/poc10/search>. 13. RAMQ (Official Mark of the Régie de L'Assurance Maladie du Québec). Liste de Médicaments. Retrieved December 5, 2023, from <https://www.ramq.gouv.qc.ca/sites/default/files/documents/liste-med-2022-08-17-en.pdf>.



**BREZTRI<sup>®</sup>  
AEROSPHERE<sup>®</sup>**  
budesonide / glycopyrronium / formoterol  
fumarate dihydrate pressurized inhalation  
suspension



**AstraZeneca**

BREZTRI<sup>®</sup>, AEROSPHERE<sup>®</sup>, and the AstraZeneca logo are registered trademarks of AstraZeneca AB, all used under license by AstraZeneca Canada Inc.

© AstraZeneca Canada Inc. 2024

1004 Middlegate Road, Suite 5000, Mississauga, Ontario, L4Y 1M4

CA-8465-E